Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically proven adenocarcinoma of the breast~* Phase I: Measurable or evaluable disease~* Phase II: Bidimensionally measurable disease~* No CNS metastases~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 65 and over~Sex:~* Female~Menopausal status:~* Postmenopausal~Performance status:~* ECOG/SAKK 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Normal peripheral blood counts~Hepatic:~* AST no greater than 2 times upper limit of normal (ULN) (no greater than 3 times ULN if liver metastases present)~Renal:~* Creatinine no greater than 1.5 times ULN~Other:~* No other prior or concurrent malignancy except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix~* No peripheral neuropathy grade 2 or higher~* No cognitive impairment or severe psychiatric disorder~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* More than 6 months since prior adjuvant chemotherapy~* No prior chemotherapy for metastatic or locally advanced disease~* No other concurrent chemotherapy~Endocrine therapy:~* Prior hormonal therapy for metastatic disease allowed~* No continuous concurrent steroids~* No concurrent systemic endocrine therapy for breast cancer~* No other concurrent endocrine therapy~Radiotherapy:~* No concurrent radiotherapy involving greater than 30% of bone marrow or mucosa~* Radiotherapy to nonindicator lesion allowed~Surgery:~* Not specified~Other:~* Bisphosphonates allowed if indicator lesion in nonbone site

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).